Palisade Asset Management’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.13M Buy
52,744
+2,115
+4% +$171K 0.38% 64
2026
Q1
$4.39M Sell
50,629
-6,209
-11% -$595K 0.44% 59
2025
Q4
$5.46M Sell
56,838
-4,635
-8% -$450K 0.53% 50
2025
Q3
$5.85M Sell
61,473
-42
-0.1% -$3.86K 0.54% 50
2025
Q2
$5.36M Buy
61,515
+2,434
+4% +$206K 0.53% 49
2025
Q1
$5.31M Buy
59,081
+3,035
+5% +$272K 0.55% 49
2024
Q4
$4.48M Sell
56,046
-294
-0.5% -$25.5K 0.45% 53
2024
Q3
$5.07M Buy
56,340
+1,076
+2% +$90.5K 0.5% 50
2024
Q2
$4.35M Sell
55,264
-3,559
-6% -$292K 0.45% 54
2024
Q1
$5.13M Sell
58,823
-268
-0.5% -$22.9K 0.5% 54
2023
Q4
$4.87M Buy
59,091
+636
+1% +$48.5K 0.53% 52
2023
Q3
$4.58M Buy
58,455
+728
+1% +$60.9K 0.56% 52
2023
Q2
$5.09M Buy
57,727
+3,119
+6% +$269K 0.59% 53
2023
Q1
$4.4M Buy
54,608
+17,486
+47% +$1.43M 0.54% 57
2022
Q4
$2.89M Sell
37,122
-986
-3% -$79.9K 0.33% 74
2022
Q3
$3.08M Buy
38,108
+306
+0.8% +$27.5K 0.42% 61
2022
Q2
$3.39M Buy
37,802
+626
+2% +$63.4K 0.44% 64
2022
Q1
$4.13M Buy
37,176
+4,158
+13% +$439K 0.47% 61
2021
Q4
$3.42M Buy
33,018
+133
+0.4% +$15.4K 0.38% 65
2021
Q3
$4.12M Sell
32,885
-48
-0.1% -$6.21K 0.5% 59
2021
Q2
$4.09M Sell
32,933
-1,010
-3% -$127K 0.48% 60
2021
Q1
$4.01M Sell
33,943
-1,083
-3% -$127K 0.52% 59
2020
Q4
$4.1M Sell
35,026
-329
-0.9% -$36.2K 0.56% 58
2020
Q3
$3.67M Buy
35,355
+1,998
+6% +$201K 0.55% 56
2020
Q2
$3.06M Buy
33,357
+17
+0.1% +$1.63K 0.49% 60
2020
Q1
$3.01M Sell
33,340
-661
-2% -$70.3K 0.55% 57
2019
Q4
$3.86M Buy
34,001
+156
+0.5% +$17.1K 0.56% 54
2019
Q3
$3.68M Sell
33,845
-285
-0.8% -$29.7K 0.56% 53
2019
Q2
$3.32M Sell
34,130
-100
-0.3% -$9.13K 0.52% 58
2019
Q1
$3.12M Sell
34,230
-480
-1% -$43K 0.49% 61
2018
Q4
$3.16M Buy
34,710
+180
+0.5% +$16.8K 0.46% 53
2018
Q3
$3.4M Sell
34,530
-384
-1% -$35.5K 0.45% 55
2018
Q2
$2.99M Buy
34,914
+115
+0.3% +$9.61K 0.43% 57
2018
Q1
$2.79M Buy
34,799
+1,050
+3% +$86.6K 0.42% 57
2017
Q4
$2.73M Sell
33,749
-400
-1% -$32K 0.43% 57
2017
Q3
$2.66M Buy
34,149
+2,785
+9% +$231K 0.48% 55
2017
Q2
$2.78M Sell
31,364
-500
-2% -$42.2K 0.55% 49
2017
Q1
$2.57M Buy
31,864
+200
+0.6% +$15.6K 0.47% 49
2016
Q4
$2.25M Sell
31,664
-9,300
-23% -$731K 0.43% 50
2016
Q3
$3.54M Sell
40,964
-2,682
-6% -$234K 0.66% 44
2016
Q2
$3.79M Sell
43,646
-200
-0.5% -$16.2K 0.72% 41
2016
Q1
$3.29M Buy
43,846
+3,550
+9% +$267K 0.64% 44
2015
Q4
$3.1M Sell
40,296
-14,414
-26% -$1.09M 0.66% 43
2015
Q3
$3.66M Sell
54,710
-3,777
-6% -$278K 0.82% 39
2015
Q2
$4.33M Sell
58,487
-1,085
-2% -$82.9K 0.86% 35
2015
Q1
$4.65M Buy
59,572
+3,090
+5% +$234K 0.91% 34
2014
Q4
$4.08M Sell
56,482
-4,075
-7% -$283K 0.8% 36
2014
Q3
$3.75M Sell
60,557
-622
-1% -$39.5K 0.77% 37
2014
Q2
$3.9M Buy
61,179
+303
+0.5% +$18.4K 0.82% 33
2014
Q1
$3.75M Buy
60,876
+200
+0.3% +$11.7K 0.82% 36
2013
Q4
$3.48M Buy
60,676
+5,150
+9% +$292K 0.79% 37
2013
Q3
$2.96M Sell
55,526
-12,425
-18% -$669K 0.75% 39
2013
Q2
$3.5M Buy
+67,951
New +$3.36M 0.88% 36

Other funds holding MDT

Palisade Asset Management's MDT Position: Q2 2026 in Review

Palisade Asset Management increased its Medtronic (MDT) stake by 4.2% in Q2 2026, buying an estimated $171K and bringing the position to 52,744 shares worth $4.13M. The position accounts for 0.38% of the portfolio, ranked #64.

Palisade Asset Management first reported a position in MDT in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.85M in Q3 2025. 606 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Palisade Asset Management held 52,744 shares of Medtronic worth $4.13M as of Q2 2026.
  • Palisade Asset Management bought 2,115 Medtronic shares in Q2 2026, an estimated $171K.
  • Medtronic made up 0.38% of Palisade Asset Management's portfolio in Q2 2026, its #64 holding.
  • Palisade Asset Management first reported a position in Medtronic in Q2 2013 and has held it in 53 quarters since.
  • Palisade Asset Management's Medtronic position peaked at $5.85M in Q3 2025.
  • 606 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Palisade Asset Management's 13F filing for Q2 2026, filed 20 Jul 2026.